MediciNova IncNASDAQ:MNOV
- LAST PRICE2.1900
- TODAY'S CHANGE (%)-0.0100 (-0.4545%)
- Bid / Lots1.8000/ 3
- Ask / Lots2.2800/ 3
- Open / Previous Close2.1701 / 2.2000
- Day Range
- 52 Week Range
- Volume6,793
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | MNOV |
|---|---|---|
| 11:08 ET | 200 | 2.1701 |
| 11:58 ET | 584 | 2.18 |
| 12:56 ET | 100 | 2.18 |
| 01:19 ET | 1016 | 2.18 |
| 02:04 ET | 100 | 2.18 |
| 02:06 ET | 100 | 2.18 |
| 03:30 ET | 100 | 2.18 |
| 03:36 ET | 2500 | 2.1973 |
| 03:54 ET | 100 | 2.18 |
| 03:57 ET | 100 | 2.18 |
| 03:59 ET | 100 | 2.19 |
May 15, 2023
MediciNova Gets European Notice of Intention to Grant for Microorganism Infection Treatment Patent, from 4:43AM ET on Monday May 15, 2023 by MT Newswires
4:43AM ET on Monday May 15, 2023 by MT Newswires
May 14, 2023
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
MediciNova Inc | 107.9M | -7.9x | --- |
CEL-SCI Corp | 107.8M | -3.0x | --- |
Genenta Science SPA | 100.4M | -11.7x | --- |
Talaris Therapeutics Inc | 107.1M | -1.3x | --- |
Panbela Therapeutics Inc | 106.8M | 0.0x | --- |
Enzolytics Inc | 105.8M | -0.4x | --- |
Company Information
MediciNova, Inc. is a biopharmaceutical company. The Company is focused on developing therapeutics for the treatment of serious diseases with unmet medical needs and a commercial focus on the United States market. It is focused on its development activities on MN-166 (ibudilast) and MN-001 (tipelukast). Its ibudilast is for neurological and other disorders, such as progressive multiple sclerosis (MS), amyotrophic lateral sclerosis (ALS), chemotherapy-induced peripheral neuropathy, degenerative cervical myelopathy, glioblastoma, substance dependence and addiction, and prevention of acute respiratory distress syndrome. Its tipelukast is for fibrotic diseases, such as nonalcoholic fatty liver disease (NAFLD) and idiopathic pulmonary fibrosis (IPF). The Company's pipeline also includes MN-221 (bedoradrine) for the treatment of acute exacerbation of asthma and MN-029 (denibulin) for solid tumor cancers. Its ibudilast is in development for various neurological diseases and other diseases.
Contact Information
- Headquarters
- SUITE 650, 4275 EXECUTIVE SQUARELA JOLLA, CA, United States 92037
- Phone
- 858-373-1500
- Fax
- 858-404-0048
Executives
- Independent Chairman of the Board
- Jeffrey Himawan
- President, Chief Executive Officer, Director
- Yuichi Iwaki
- Chief Financial Officer
- Jason Kruger
- Vice President
- Geoffrey O'brien
- Chief Medical Officer, Director
- Kazuko Matsuda
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $107.9M |
|---|---|
Revenue (TTM) | $0.00 |
Shares Outstanding | 49.0M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 0.99 |
EPS | $-0.28 |
Book Value | $1.43 |
P/E Ratio | -7.9x |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | --- |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
